LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Radiation dermatitis is a common side-effect of radiation therapy in cancer patients who frequently can experience redness, pain, crusting, and even ulceration of the skin causing suffering and treatment interruption. A recent retrospective study by DeLand demonstrated that administering light emitting diode (LED) photomodulation after each radiation treatment for breast cancer decreased radiation dermatitis in a majority of patients. LED photomodulation is a process by which specific sequences of light are used to regulate or manipulate cell activity without causing heat or damage to the skin. Each LED treatment is painless and is completed in usually less than one minute. LED photomodulation may reduce the suffering associated with radiation treatments, improve cosmetic outcome in radiation fields, and eliminate breaks in radiation treatments which may be required because of severe ulcerating reactions.

This study will attempt to replicate the findings of Dr. DeLand's study by randomly assigning at least 40 breast cancer patients to either a treatment group or to a control group. The treatment group will receive LED photomodulation treatments before and after each radiation treatment with the Gentlewaves Select™ handheld high energy 590nm LED array using specific sequences of pulses used in other studies; the treatment group will also receive 7 additional treatments over 2 weeks after their radiation treatment course is completed. The control group will receive no LED treatment but will use the exact same skin care regimen as the treatment group. In addition to weekly evaluation and grading of skin reactions, subjects will be photographed under standardized conditions weekly and then photographs will be evaluated and graded by blinded dermatologists.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy

NCT03924011

Radiodermatitis Breast Cancer

COMPLETED NA

Laser Therapy for the Prevention of Radiodermatitis in Breast Cancer Patients

NCT02443493

Breast Cancer

COMPLETED NA

Photobiomodulation in Radiodermatitis in People With Breast Cancer

NCT06990165

Breast Cancer Radio Dermatitis

NOT_YET_RECRUITING NA

Photobiomodulation for Breast Cancer Radiodermatitis

NCT04059809

Breast Cancer Radiodermatitis Radiotherapy Side Effect +5 more

COMPLETED PHASE2/PHASE3

Laser Therapy for the Management of Radiation Dermatitis

NCT01932073

Radiation Dermatitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Radiation Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The enrollment goal of 40 includes 20 for each arm.

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

LED treatment with Gentlewaves Select™ handheld high energy LED array 5 to 10 minutes before each radiation treatment and again 5-10 minutes after each radiation treatment

Group Type EXPERIMENTAL

Gentlewaves Select™ handheld high energy LED array

Intervention Type DEVICE

LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment

Radiation

Intervention Type RADIATION

Weekly radiation treatment

Control

Radiation only

Group Type OTHER

Radiation

Intervention Type RADIATION

Weekly radiation treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gentlewaves Select™ handheld high energy LED array

LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment

Intervention Type DEVICE

Radiation

Weekly radiation treatment

Intervention Type RADIATION

Radiation

Weekly radiation treatment

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have clinically diagnosed breast or head and neck cancer that will be treated with radiation therapy.
* Subjects must be at least 18 years of age

Exclusion Criteria

* Subjects will not be eligible to participate if they are pregnant or lactating.
* Patients treated with partial breast irradiation techniques, brachytherapy, or other non-standard techniques will not be eligible.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No